These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 20051811)

  • 1. Cost comparison of capecitabine in patients with breast cancer.
    Rugo HS; Kohles J; Schulman KL
    Am J Clin Oncol; 2010 Dec; 33(6):550-6. PubMed ID: 20051811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer.
    Camacho FT; Wu J; Wei W; Kimmick G; Anderson RT; Balkrishnan R
    J Med Econ; 2009 Sep; 12(3):238-45. PubMed ID: 19732030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
    Verma S; Ilersich AL
    Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.
    Hurvitz S; Guerin A; Brammer M; Guardino E; Zhou ZY; Latremouille Viau D; Wu EQ; Lalla D
    Oncologist; 2014 Sep; 19(9):901-8. PubMed ID: 25085897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer.
    Chu E; Shi N; Wei W; Bendell JC; Cartwright T
    Oncology; 2009; 77(3-4):244-53. PubMed ID: 19738390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
    Reed SD; Li Y; Anstrom KJ; Schulman KA
    J Clin Oncol; 2009 May; 27(13):2185-91. PubMed ID: 19332722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Fumoleau P; Largillier R; Clippe C; Dièras V; Orfeuvre H; Lesimple T; Culine S; Audhuy B; Serin D; Curé H; Vuillemin E; Morère JF; Montestruc F; Mouri Z; Namer M
    Eur J Cancer; 2004 Mar; 40(4):536-42. PubMed ID: 14962720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Lee SH; Lee J; Park J; Park SH; Lee KE; Lee SI; Nam E; Park JO; Kim K; Jung CW; Park YS; Yoon SS; Kang WK; Lee MH; Park K; Im YH
    Med Oncol; 2004; 21(3):223-31. PubMed ID: 15456949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
    Chu E; Schulman KL; McKenna EF; Cartwright T
    Clin Colorectal Cancer; 2010 Oct; 9(4):229-37. PubMed ID: 20920995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer.
    Jones L; Hawkins N; Westwood M; Wright K; Richardson G; Riemsma R
    Health Technol Assess; 2004 Feb; 8(5):iii, xiii-xvi, 1-143. PubMed ID: 14960257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients.
    De Portu S; Mantovani LG; Ravaioli A; Tamburini E; Bollina R; Cozzi C; Grimaldi AM; Testa TE; Bianchessi C; Carteni G
    J Chemother; 2010 Apr; 22(2):125-8. PubMed ID: 20435573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer.
    Chu E; Schulman KL; Zelt S; Song X
    Cancer; 2009 Apr; 115(7):1412-23. PubMed ID: 19195048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Lee SJ; Choi YL; Park YH; Kim ST; Cho EY; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):743-51. PubMed ID: 21170649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
    Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
    Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.
    Delea TE; Tappenden P; Sofrygin O; Browning D; Amonkar MM; Karnon J; Walker MD; Cameron D
    Eur J Health Econ; 2012 Oct; 13(5):589-603. PubMed ID: 21701940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experience with capecitabine in patients with anthracycline and/or taxane-resistant recurrent breast cancer].
    Tagaya N; Nakagawa A; Mori S; Tachibana M; Kakihara Y; Hamada K; Suzuki N; Kubota K
    Gan To Kagaku Ryoho; 2005 Aug; 32(8):1135-8. PubMed ID: 16121915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
    Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients.
    Chen HH; Chen WT; Lee HC; Lin JK; Fang CY; Chou YH; Lin PC; Lin BW; Huang CC; Yeh CH; Hsu HH; Chen HC; Ting WC; Yang MC; Tan EC
    Qual Life Res; 2015 Feb; 24(2):473-84. PubMed ID: 25099199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
    Bunnell C; Vahdat L; Schwartzberg L; Gralow J; Klimovsky J; Poulart V; Peck R; Thomas E
    Clin Breast Cancer; 2008 Jun; 8(3):234-41. PubMed ID: 18650153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
    Thomas ES; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Pivot XB; Klimovsky JV; de Mendoza FH; Xu B; Campone M; Lerzo GL; Peck RA; Mukhopadhyay P; Vahdat LT; Roché HH
    J Clin Oncol; 2007 Nov; 25(33):5210-7. PubMed ID: 17968020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.